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ABSTRACT
A critical appraisal and clinical application of Skagen C, Einstein M, Lucey MR, Said A. Combination treatment with
octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol.
2009 Aug;43(7):680-5. doi: 10.1097/MCG.0b013e318188947c
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Clinical Context
On the general practice ward, a 52 year old female with a past medical history of primary biliary cirrhosis,
presented with left upper quadrant pain. Her MELD score (Model for End Stage Liver Disease) was 22 on
presentation, suggesting that she was at high risk of mortality. She was receiving weekly paracentesis, and had
been following with hepatology for liver transplantation. For her liver disease, the patient was taking ursodiol,
furosemide, spironolactone, lactulose, and rifaximin. After an extensive investigation with physical exam,
abdominal ultrasound, esophagogastroduodenoscopy, paracentesis, and chest x-ray, the patient's pain was
attributed to musculoskeletal pain of the chest wall. However, during her stay, it was noticed that her creatinine
was increasing. Her baseline creatinine prior to presentation was 1.67. During her hospitalization, her creatinine
reached a maximum of 2.87. Working with hepatology and nephrology, we diagnosed hepatorenal syndrome
(HRS). Diuretics were discontinued to improve renal perfusion. Nephrology recommended a hepatorenal cocktail
composed of octreotide, midodrine, and albumin. The internal medicine staff physician started a conversion with
the team about the hepatorenal cocktail. He was not ultimately convinced by the evidence behind the
intervention. This inspired me to research hepatorenal syndrome (HRS), intervention options, and the
effectiveness of the interventions.

Clinical Question
Does octreotide, midodrine, and albumin improve survival in patients with hepatorenal syndrome?
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Research Article
Skagen C, Einstein M, Lucey MR, Said A. Combination treatment with octreotide, midodrine, and albumin improves survival in
patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol. 2009 Aug;43(7):680-5. doi:
10.1097/MCG.0b013e318188947c

Literature Review
Hepatorenal syndrome (HRS) is one of many causes of acute kidney injury (AKI) in the context of cirrhosis. Treatment strategies have
the goal of reperfusion of the kidneys. I searched PubMed for “hepatorenal syndrome treatment.” Many of the most recent papers
evaluate terlipressin, an analogue of vasopressin. However, terlipressin is not available in the United States. While initial results are
promising1, it does not help patients and clinicians here and now. One small pilot study (N=12) looked at the effect of
norepinephrine and found norepinephrine effective.2 One study found that norepinephrine had similar outcomes compared to
terlipressin3. However, the use of norepinephrine on general medical wards is usually not possible, and therefore was not an option
for our patient. A few studies looked at the use of midodrine and octreotide. This therapy was deemed most feasible given our
patient’s clinical situation. As a search technique, I reviewed the references of a non-systematic consensus review paper published in
20164. One randomized, double-blinded, cross-over study investigated the effects of octreotide alone as a treatment, but it came to
the conclusion that there was no significant improvement in renal function5. This paper was underpowered because there were only
14 cases. One retrospective study compared octreotide/midodrine to dopamine. It showed a significant positive outcome with
octreotide/midodrine, but the study only had 13 participants6. Another retrospective study used octreotide, midodrine, and albumin,
all of which are generally options to a patient on the general medical wards. The study had 81 participants. The study also claimed to
have a significant outcome for patients with hepatorenal syndrome but the methodology was weak for an observational trial7. The
study selected for this appraisal showed a significant outcome with the use of octreotide, midodrine, and albumin, similar to the
previous study, but had a total of 162 participants8.

Critical Appraisal
The paper is a retrospective study from a single hospital between the years 1997-2004. Billing database information was used for
case finding using ICD-9 codes. The authors gave the impression that they included all patients who received the specified treatment,
although the methodology for case finding was only as good as was achievable using their retrospective methods. Historical controls
were identified using the same methods, and this group of patients were a subset of patients prior to availability of the therapy
studied. The study has a 3b level of evidence using the Oxford Centre for Evidence-Based Medicine. Selected participants were
identified to have HRS. The authors used reasonable inclusion and exclusion criteria in what seemed to be a consistent manner. Our
patient would have been eligible for inclusion. There were 75 in the treatment group who received octreotide, midodrine, and
albumin, and 87 in the control group, for a total of 162 cases. Both groups were similar in regard to MELD score, baseline GFR,
baseline creatinine, liver disease etiology, and severity of HRS (HRS 1 and 2). Although a handful of objective measurements are
similar between both groups, other confounding factors that were different between the groups cannot be ascertained. These
confounding variables may be responsible for the end results of the study. Once the treatment was available, the study does not
include those that did not receive treatment in the statistical analysis. Those that did not receive the treatment might not have
received it for a variety of reasons, creating a bias between the groups. This is perhaps the critical flaw in the paper. The authors did
not compare patients who received the therapy to patients who did not receive the therapy once it became available. This limits our
ability to assess the bias. These ignored individuals after May 2001 were inevitably present in the pre-May 2001 group and therefore
included in the control group, another source of bias. Due to the retrospective nature of this paper, the treatment groups were not
randomized and were not blinded. No inference of cause and effect can be made using this study methodology. In light of this, the
reader must be cautious during clinical application.
All-cause mortality is possible to determine in a retrospective study, given the ability to determine living status with social security
records. However, morbidity is a more difficult task. The other outcomes this study looked into besides mortality were glomerular
filtration rate (GFR), liver transplant rates, and dialysis. There are many other measurements of outcome that could be determined
and could influence the decision to use treatment.
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The overall survival between the treatment group and control group at 3 months was 53% vs. 27% (p < 0.0001). The median survival
between the groups is 101 days vs. 18 days, respectively. This has the appearance of a very large effect size, but again, caution
should be used when drawing conclusions. Mortality as the outcome is less likely to be a source of ascertation bias. The number
needed to treat with midodrine-octreotide-albumin compared to standard care over a three month period of time is calculated to be
3.8. The study also calculated the survival rates between individuals with HRS 1 and HRS 2. HRS 1 three-month survival was 44% vs.
18% (p < 0.0004), number needed to treat being 3.8. HRS 2 three-month survival was 75% vs 40% (p < 0.007), number needed to
treat being 2.9. All p values indicate statistically significant results.

Clinical Application
The gold standard for a patient with liver cirrhosis is liver transplantation, especially if he/she is burdened by
hepatorenal syndrome. The scarcity of resources, however, requires us as physicians to develop alternative
treatment options. This study by Skagen, et al. shows us that the use of octreotide, midodrine, and albumin have a
positive outcome on survival rates for patients with hepatorenal syndrome. As a retrospective study, this paper
provides only modest guidance to clinical application. Telling a patient that there is improved survival sounds much
different than telling him/her that median survival increases from 18 to 101 days; the difference is even greater
when explaining we must treat 3.8 people to see improvement in 1. This is where the discussion of side effects and
number needed to harm comes into play, but that is beyond the scope of this paper and the study appraised.
Ultimately, the patient has the right to decide if the outcome is significant within their life context.
For our patient, it was reasonable for the patient and clinicians to initiate treatment with midodrine, octreotide,
and albumin (HRS cocktail). Our patient had many similar features compared to the patients in the study: similar
age, MELD score, race. One example of how our patient differed is that the majority of the patients in the study
had liver disease due to alcohol, hepatitis C, and hepatitis B, while our patient’s was due to primary biliary
cirrhosis. Ultimately, based on our pathophysiologic understanding of this disease, it is reasonable to say that our
patient was similar to the patients of this study. Improved survival is noted at 3 months. This gives our a greater
chance to receive a liver for transplantation, which is the ultimate treatment for hepatorenal syndrome.
In other situations, however, improved survival may not be valued as much. Another patient comes to mind, who
also had end-stage liver cirrhosis, but did not meet inclusion criteria for liver transplantation. If he were to be faced
with the clinical situation of HRS, how would he value the statistical numbers of improved survival? I cannot speak
for him, but it was apparent after many early-morning discussions that he wanted to leave the hospital as soon as
possible so that he could spend his statistically-limited days with his family. Also, as mentioned earlier as a
limitation of this retrospective study, strong analysis of morbidity is difficult. Is there potentially a side effect of the
HRS cocktail that may impair his final days with his family? In this case of no transplantation option the
interpretation of improved survival changes, and can only be made on a case-by-case basis.
Although HRS cocktail may be appropriate in some patients, it is also reasonable to forego such therapy, given the
lack of any strong evidence of its efficacy.
Learning points
1.) Midodrine, Octreotide, and Albumin may improve survival for patients with hepatorenal syndrome at 3
months, improving chances to be selected for liver transplantation, if eligible.
2.) Retrospective studies have limitations. Given the overall paucity of studies on this therapy despite lack of
other treatments, one has to wonder if the benefits are convincing enough to initiate a randomized doubleblinded controlled trial.
3.) Terlipressin has been shown to be superior to the HRS cocktail, but it is not yet available in our practice.
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